Starting in 2021, Sartorius will source the energy needs of its locations in Germany from hydroelectric power. Its three company sites in Göttingen, Guxhagen and Ulm currently account for around half of the Group’s energy consumption. Conversion to renewable energy will thus enable the company to reduce its CO2 emissions by 30 percent.
The switch to hydropower is part of the Sartorius Group sustainability strategy aimed at far-reaching decarbonization. “We are systematically identifying opportunities to reduce emissions and the consumption of resources and, in this effort, are also focusing on sustainable energy supply. By using hydroelectric power, we will be able to reduce our CO2 footprint significantly. We are planning to switch over progressively to renewable energy sources at our international sites as well,” said Executive Board Chairman and CEO Joachim Kreuzburg.
Electricity will be generated from moving water by LEW Wasserkraft GmbH with its hydroelectric power plants located on the upper Danube. In an EU-wide pilot project for ecological flood protection, the company is additionally committed to upgrading the riverbanks of the Danube and protecting the adjacent floodplain forests. In this way, valuable habitats for animals and plants will be created. When Sartorius selects suppliers, their sustainability policy is an important criterion, because for the company, sustainability means engaging in responsible activities over the long term – with respect to business partners, employees, natural resources and society.
A profile of Sartorious
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83billion euros. At the end of 2019, more than 9,000 people were employed at the Group’s approximately 60manufacturing and sales sites, serving customers around the globe
El gen AtCDF3 promueve una mayor producción de az...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Han estudiado si la aterosclerosis asociada a HGPS puede evitarse medi...
